Sudarshan Pharma Industries Ltd., a specialty chemical company headquartered in Mumbai, recently announced a 1:10 stock split after an impressive 403% surge in its share price this year. Originally scheduled for November 18, the record date for this split has been updated to November 23, 2024, due to administrative adjustments. By splitting each share into ten, the company aims to enhance market liquidity and make the stock more accessible to smaller investors. Following the split, the face value of each share will be reduced from ₹10 to ₹1, thereby multiplying the total share count by ten, without altering the company’s overall market valuation.
The stock has seen an extraordinary rise, gaining 483.41% over the past six months, which ranks it among 2024’s top-performing small-cap stocks. For example, an investor who put in ₹50,000 in May 2024, when shares were trading at ₹69.92, would now hold a total corpus of approximately ₹2,91,705. This surge highlights Sudarshan Pharma’s robust market performance and positions it as a multi-bagger in the specialty chemicals and pharmaceutical sectors.
Founded in 2008, Sudarshan Pharma went public in 2016 and has since developed a diversified portfolio across pharmaceuticals, specialty chemicals, and intermediates used in industries like paints, food, and adhesives. The company has a strong presence in India and also exports to markets in the UK, Australia, and across the MENA region. Ventura Securities recently highlighted Sudarshan Pharma’s potential for growth, noting the impact of its stock split announcement and its strategic expansions. For long-term investors, the company’s performance, along with its planned split, suggests promising growth opportunities in the specialty chemical and pharmaceutical industries.
Disclaimer; The information provided in this blog is for informational purposes only and should not be considered as financial advice. Always conduct your own research or consult with a financial advisor before making any investment decisions. The author does not take any responsibility for any financial outcomes resulting from the use of this information.
Leave a Reply